Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs
- 1 November 2008
- journal article
- Published by Elsevier BV in Chemico-Biological Interactions
- Vol. 178 (1-3), 221-227
- https://doi.org/10.1016/j.cbi.2008.10.024
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Progesterone Receptor Inhibits Aromatase and Inflammatory Response Pathways in Breast Cancer Cells via Ligand-Dependent and Ligand-Independent MechanismsMolecular Endocrinology, 2008
- Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breastEndocrine-Related Cancer, 2008
- Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibitionSteroids, 2008
- An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignanciesBiochemical Pharmacology, 2008
- 15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits Transcriptional Activity of Estrogen Receptor-α via Covalent Modification of DNA-Binding DomainCancer Research, 2007
- 17β-Hydroxysteroid Dehydrogenase 14 Affects Estradiol Levels in Breast Cancer Cells and Is a Prognostic Marker in Estrogen Receptor–Positive Breast CancerCancer Research, 2006
- Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissuesMolecular and Cellular Endocrinology, 2006
- Sex steroid-producing enzymes in human breast cancerEndocrine-Related Cancer, 2005
- Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostateSteroids, 2004
- 17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast CancerCancer Research, 2004